Alister Campbell, of Dotmatics, details how artificial intelligence is changing the drug discovery process. Dr. Townsend details the science behind aldosterone, the hormone that regulates sodium and helps regulate blood pressure. Dr. Townsend discusses hypertension and how not adhering to medications is the biggest issue for patients. Dr. Timothy Yap discusses the PETRA trial, which showed the efficacy of saruparib in treating HER2-negative breast cancer. Drs. White and Berman consider how the post hoc analysis of CROSSFIRE elucidates the benefit of ablative therapy with IO. Drs. White and Berman share insights gained from the CROSSFIRE trial comparing IRE with SBRT in advanced pancreatic cancer. Dr. William Jarnagin discusses his recent study on characterizing the heterogeneity of intrahepatic cholangiocarcinoma. Dr. Samilia Obeng-Gyasi discusses how social factors can impact outcomes in breast cancer patients. Stacy Stephens explains how autonomous security robots are boosting surveillance and communication in hospitals. Arun Krishna, of AstraZeneca, talks about the phase 3 FLAURA2 trial, which assessed Tagrisso in patients with NSCLC. Dr. Pant discusses the relationship between T cell response magnitude and tumor biomarker reduction. Michael Spigler presents highlights of the American Kidney Fund's fifth annual Kidney Action Week. Dr. Griffin shares data from their real-world study on pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. Dr. Grunwald of the Atrium Health Levine Cancer Institute, discusses caring for patients with PV on rare disease day. Dr. Bob Walker discusses high blood pressure in the context of severe COVID-19 infection. Dr. Brooks explains the association between male sex and 5-FU exposure. Dr. Pakbaz describes some of the difficulties faced by patients with SCD as they switch from pediatric to adult programs. Marisa Bittoni, PhD, talks about a large-scale study exploring factors that lead to lung cancer in patients younger than 50. Cynthia Miller, MD, MPH, FACP, discusses why early Lp(a) screening may help prevent cardiovascular disease. Drs. Grant, Sutin, and Lin discuss their pilot study investigating cerebral hemodynamics in infants with sickle cell disease. What does the data and overall understanding of VEGF-TKIs tell us about which patients are optimal candidates for tivozanib?